News | January 22, 2025
Sunshine Biopharma launches Olanzapine and Olanzapine ODT
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
Morepen Laboratories approves hiving off of medical devices business
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The biosimilar Ustekinumab has been developed and manufactured by the company
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
This facility marks a significant milestone in transforming the global food industr
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Final decision from the European Commission is anticipated within the coming months
Subscribe To Our Newsletter & Stay Updated
